Published in Blood Weekly, April 22nd, 1996
Truquant BR RIA is the first breast tumor marker test to receive expedited review by the FDA, and is the first such test to be cleared for marketing in the United States. Truquant BR RIA is a blood test that can detect breast cancer recurrence in women previously treated for Stage II and Stage III breast cancer. There are currently more than one million women living in the United States who have been diagnosed with Stage II and Stage III breast cancer.
"Once you've had breast cancer, the fear...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.